Kenneth Erland Johnson

Insider Reports History

Entity
Individual
Location
C/O Xeris Pharmaceuticals, Inc., 180 N. Lasalle Street, Suite 1800, Chicago, IL
Signature
/s/ Beth Hecht, as Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Kenneth Erland Johnson:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Xeris Biopharma Holdings, Inc. Senior Vice President, Global Development and Medical Affairs Common Stock 373K $918K $2.46 Jan 31, 2024 Direct
XERIS PHARMACEUTICALS INC Sr. VP Clinical Development, Regulatory, Quality Assurance & Medical Affairs Common Stock 0 Oct 5, 2021 Direct
XERIS PHARMACEUTICALS INC Sr. VP Clinical Development, Regulatory, Quality Assurance & Medical Affairs Stock Option (Right to Buy) 0 Oct 5, 2021 Direct

Insider Reports Filed by Kenneth Erland Johnson

Symbol Company Period Transactions Value $ Form Type Date Filed Role
XERS Xeris Biopharma Holdings, Inc. Jan 31, 2024 1 $0 4 Jan 31, 2024 Senior Vice President, Global Development and Medical Affairs
XERS Xeris Biopharma Holdings, Inc. Jan 31, 2023 1 $0 4 Feb 1, 2023 Senior Vice President, Global Development and Medical Affairs
XERS Xeris Biopharma Holdings, Inc. Jan 29, 2022 8 -$146K 4 Aug 9, 2024 Senior Vice President, Global Development and Medical Affairs
XERS Xeris Biopharma Holdings, Inc. Jan 3, 2022 1 $0 4 Jan 5, 2022 Senior Vice President, Global Development and Medical Affairs
XERS Xeris Biopharma Holdings, Inc. Oct 5, 2021 8 $0 4 Oct 5, 2021 Senior Vice President, Global Development and Medical Affairs
XERS XERIS PHARMACEUTICALS INC Oct 5, 2021 8 $0 4 Oct 5, 2021 Sr. VP Clinical Development, Regulatory, Quality Assurance & Medical Affairs
XERS Xeris Biopharma Holdings, Inc. Oct 5, 2021 0 $0 3 Oct 5, 2021 Title: Senior Vice President, Global Development and Medical Affairs Exhibit 24 - Power of Attorney